Human immunodeficiency virus type 1 clade B antigens (HIV-1 clade B antigens) (HIV-1 clade B antigens)

Human immunodeficiency virus type 1 (HIV-1) clade B antigens are a group of viral proteins derived from the most prevalent HIV-1 subtype in North America and Europe (NIH, 2023). These antigens include structural proteins like Gag (p24), envelope glycoproteins such as gp120 and gp41, and essential enzymes like reverse transcriptase and protease (UniProt, 2023). They serve as the primary targets for both preventative and therapeutic vaccine strategies, which aim to induce robust humoral and cellular immune responses (IAVI, 2022). Specifically, the envelope glycoproteins are targeted by broadly neutralizing antibodies to prevent the virus from entering CD4+ T cells. In clinical research, these antigens are often delivered via mRNA or viral vector platforms to evaluate their ability to generate protective immunity against HIV-1 infection. Monitoring the immune response to these specific antigens is crucial for the development of a global HIV vaccine, although high viral mutation rates continue to present a significant challenge (PubMed, 2021).

Other names

HIV-1 subtype B antigensHIV-1 group M subtype B antigensHIV-1 clade B proteinsHIV-1 B antigens

Vaccines containing these antigens aim to prime the immune system to recognize and neutralize the virus by eliciting broadly neutralizing antibodies (bNAbs) and activating T-cell responses (IAVI, 2022). Monoclonal antibodies bind to specific epitopes on these antigens, such as the CD4 binding site on gp120, to block viral entry into host cells (NIH, 2023). Antiretroviral drugs inhibit the enzymatic activity of specific antigen components like reverse transcriptase or protease to prevent viral replication (PubMed, 2021).